At a glance
ClinicalIndex Comparison RecordPhase 3Active· 30 enrolled
Drug / intervention
Baricitinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Active-Controlled, Safety, and Efficacy Study of Oral Baricitinib in Patients From 2 Years to Less Than 18 Years Old With Active Juvenile Idiopathic Arthritis-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis
In Brief
A Phase 3 clinical trial evaluating Baricitinib and Adalimumab for Uveitis. Active but no longer recruiting, targeting 30 participants across 20 sites in 5 countries.
Detailed Summary
The reason for this study is to see if the study drug baricitinib given orally is safe and effective in participants with active juvenile idiopathic arthritis (JIA)-associated uveitis or chronic anterior antinuclear antibody-positive uveitis from 2 years to less than 18 years old.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUveitis
CountriesFrance, Germany, Italy, Spain, United Kingdom
Collaborators--
Timeline
Phase 3Active
202020212022202320242025202620272028
First PostedSep 2019
Enrollment StartOct 2019
Primary CompletionJul 2023
TodayJul 2026
Study CompletionJul 2028
First PostedSep 12, 2019
Enrollment StartOct 16, 2019
Primary CompletionJul 17, 2023
Study CompletionJul 1, 2028
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 6.8 years ago
Interventions
Baricitinibdrug
Administered orally
Adalimumabdrug
Administered SC